Rocket Lab (NASDAQ: RKLB) shares plunged 6.6% on May 21, 2026, after the company disclosed a $3 billion at-the-market equity distribution agreement with 16 financial institutions. The move spooked investors already on edge from valuation concerns and the delayed Neutron rocket timeline, despite the stock’s spectacular 82.5% year-to-date gain and a 402% surge over the past 12 months.
The SEC filing, submitted on May 20, revealed that Rocket Lab could gradually sell up to $3 billion in stock through sales agents including Goldman Sachs, Morgan Stanley, BofA Securities, Deutsche Bank Securities, and several others. Forward sale provisions were also outlined, under which certain banks would borrow and sell shares to hedge their positions, amplifying dilution fears. The structure does not force immediate issuance, but the sheer size of the potential offering—relative to the company’s ~$75.9 billion market cap—triggered a sharp sell-off.
The announcement punctured a rally fueled by Wall Street’s bullishness ahead of the highly anticipated SpaceX IPO. Analysts had recently raised price targets for RKLB: New Street Research to $150, Deutsche Bank to $120, and Needham to $121. Rocket Lab’s revenue grew 63.5% in the first quarter to $200.3 million, and its backlog hit a record $2.2 billion, driven by 31 new Electron and HASTE contracts. Yet the stock’s forward price-to-sales ratio of 81 and the risk of a “buy the rumor, sell the news” reaction to the SpaceX listing were already weighing on sentiment.
Technical analysis also flagged risks. RKLB had recently touched an all-time high of $139, completing a cup-and-handle pattern with a breakout above $99.72. However, the stock traded far above its 50-day and 100-day moving averages, suggesting a potential mean reversion to support near $100.
The equity distribution agreement does not obligate Rocket Lab to sell shares immediately, but the market’s reaction underscores sensitivity to any hint of dilution in a high-valuation environment.
